Grifols SA (GRLS)

10.025
-0.860(-7.90%)
  • Volume:
    2,769,499
  • Bid/Ask:
    9.970/10.070
  • Day's Range:
    9.450 - 10.940
Unusual trading volume

Grifols has doubled (or more) its daily average of shares traded over the last 3 months. High volumes usually indicate new trends and larger share price movements.

1 / 2

GRLS Overview

Prev. Close
10.025
Day's Range
9.45-10.94
Revenue
9.23B
Open
10.94
52 wk Range
9.45-22.64
EPS
0.088
Volume
2,769,499
Market Cap
6.11B
Dividend (Yield)
0.426
(2.28%)
Average Volume (3m)
1,039,227
P/E Ratio
135.07
Beta
0.136
1-Year Change
-54.37%
Shares Outstanding
678,910,694
Next Earnings Date
03 Nov 2022
What is your sentiment on Grifols?
or
Market is currently closed. Voting is open during market hours.

Grifols SA News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • Grifols ADR Earnings, Revenue miss in Q4
    • ByInvesting.com-

    Investing.com - Grifols ADR reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Grifols ADR announced earnings...

  • Grifols Earnings, Revenue miss in Q4
    • ByInvesting.com-

    Investing.com - Grifols reported on Monday fourth quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. Grifols announced earnings per...

  • Grifols Earnings, Revenue beat in Q2
    • ByInvesting.com-

    Investing.com - Grifols reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations. Grifols announced earnings per share of...

Grifols SA Analysis

Grifols SA Company Profile

Grifols SA Company Profile

Employees
23245
Market
Spain
  • Type:Equity
  • Market:Spain
  • ISIN:ES0171996087

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Read More

Analyst Price Target

Average21.711 (+116.57% Upside)
High30
Low13
Price10.025
No. of Analysts17
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell